Oryzon Genomics - A year of data readouts
Oryzon has a total of five Phase II studies ongoing with its two lead assets iadademstat (formerly ORY-1001) and vafidemstat (formerly ORY-2001), which are all expected to have preliminary data readouts in 2019. In November 2018, the company announced the first patients had been recruited in to the iadademstat Phase IIa small cell lung cancer (CLEPSIDRA) and acute myeloid leukaemia (ALICE) studies. A scientific paper was recently published by a third party in Science Signalling, which has revealed a potential mechanism of action of iadademstat (ORY-1001) in pre-clinical SCLC models; this is supportive to Oryzon’s ongoing Phase II study in SCLC. Our valuation is slightly higher at €364m or €9.3/share.Oryzon Genomics SA is a Spain-based biopharmaceutical company. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases. The Company's business model focuses on identifying biomarkers that can be translated in new therapeutic targets, as well as on investing in programs, mainly through the development of small molecules for two main indications: cancer and neurodegeneration. The Company develops investigational medicines till proof of concept (POC) phase and then partners the program with pharmaceutical entities, which are able to get the approval from drug agencies to bring these medicines to the patients. It cooperates with Roche. The Company is a subsidiary of Laboratorio Reig Jofre SA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.